Genmab A/S (OTCMKTS:GNMSF - Get Free Report) was the target of a large drop in short interest during the month of August. As of August 15th, there was short interest totaling 22,800 shares, a drop of 25.2% from the July 31st total of 30,500 shares. Based on an average daily volume of 1,800 shares, the short-interest ratio is currently 12.7 days. Based on an average daily volume of 1,800 shares, the short-interest ratio is currently 12.7 days.
Genmab A/S Price Performance
Shares of OTCMKTS:GNMSF remained flat at $284.18 during mid-day trading on Friday. The stock has a market cap of $18.78 billion, a price-to-earnings ratio of 14.27 and a beta of 0.90. Genmab A/S has a fifty-two week low of $170.00 and a fifty-two week high of $284.18. The firm's 50-day simple moving average is $232.82 and its two-hundred day simple moving average is $214.29.
Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $5.42 EPS for the quarter, topping the consensus estimate of $3.99 by $1.43. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The company had revenue of $925.00 million during the quarter, compared to the consensus estimate of $949.06 million.
About Genmab A/S
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Recommended Stories
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
